%20--%3e%3cdefs%3e%3cstyle%3e%20.st0%20{%20fill:%20%23fff;%20}%20%3c/style%3e%3c/defs%3e%3cpath%20class='st0'%20d='M26.036.129C10.532.129,0,11.725,0,26.029s10.883,25.899,26.036,25.899c11.829,0,20.428-6.6,23.938-15.983l-13.165-.147c-2.436,3.026-6.115,4.93-10.677,4.93-6.945,0-12.242-4.724-13.741-11.122l39.12-.039c.138-1.157.209-2.338.209-3.538C51.72,11.725,41.1.129,26.036.129ZM13.144,19.67c2.092-5.128,6.816-8.69,12.987-8.69,6.003,0,10.709,3.571,12.799,8.708l-25.786-.018ZM117.213,18.171c0-1.845,1.504-3.341,3.359-3.341l17.801.005V.129h-19.144c-10.017,0-18.137,8.078-18.137,18.042v18.381l-22.335-.006c-6.028,0-10.915-4.862-10.915-10.858s4.887-10.858,10.915-10.858h20.992V.129h-20.992c-14.376,0-26.029,11.593-26.029,25.893s11.654,25.893,26.029,25.893h22.335v38.088h16.121v-38.088h35.602v-15.363h-35.602v-18.381ZM148.784,40.478v7.434h-35.266v38.417h-8.397v-38.417s-14.216-.005-26.365-.005-21.999-9.798-21.999-21.884,9.849-21.884,21.999-21.884h16.961v6.682h-16.987c-8.24,0-14.92,6.645-14.92,14.842s6.68,14.842,14.92,14.842l26.392-.026v-22.307c0-7.75,6.316-14.032,14.106-14.032h15.45v6.688l-14.106-.005c-4.081,0-7.389,3.291-7.389,7.35v22.307h35.602ZM179.685,20.691c-5.483-1.881-10.305-3.198-10.305-6.019v-.188c0-1.975,1.796-3.48,5.294-3.48,3.687,0,8.698,1.787,13.709,4.703l5.483-9.875C188.383,2.163,181.387,0,174.958,0,164.747,0,156.427,5.737,156.427,15.988v.188c0,9.781,8.036,13.073,15.127,15.142,5.578,1.693,10.494,2.728,10.494,5.831v.188c0,2.257-1.891,3.762-6.051,3.762-4.727,0-10.494-2.069-15.978-6.019l-6.145,9.405c6.713,5.267,14.654,7.618,21.745,7.618,10.967,0,19.381-5.079,19.381-16.27v-.188c0-9.217-8.225-12.602-15.316-14.954Z'/%3e%3c/svg%3e)
Co-trimoxazole
C
MEDICATION TYPE
Antibiotic
INDICATIONS
Treatment of Burkholderia cepacia, Achromobacter, S.maltophilia, H influenza, MSSA, prophylaxis and treatment of PCP, Mycobacterium abscessus infection.
DRUG INTERACTIONS
Amiodarone
Increased risk of ventricular arrhythmias.
Cyclosporin
Renal impairment.
Methotrexate
Increased antifolate effect.
Phenytoin
Antifolate effect increased also phenytoin level increased.
Sulphonylureas
Antidiabetic effect enhanced.
Warfarin
Increases INR.
NOTES
Monitor FBC, U&Es. Risk of severe cutaneous reactions — counsel.
MEDICAL WARNING
Co-trimoxazole should only be administered under the supervision of a healthcare professional. Always verify against current BNF and your local CF protocol before prescribing.